08:00 , Jan 2, 2012 |  BC Week In Review  |  Clinical News

GSK2586881: Phase IIa started

GlaxoSmithKline began a U.S. and Canadian Phase IIa trial to evaluate GSK2586881 in ALS patients. GSK has exclusive, worldwide rights to develop and commercialize the compound from Apeiron (see BioCentury, Feb. 8, 2010). Apeiron Biologics...
08:00 , Feb 28, 2011 |  BioCentury  |  Product Development

Two for one in neuroblastoma

By activating multiple elements of the host's immune system, Apeiron Biologics AG believes its mAb fused to IL-2 will provide a one-two punch to neuroblastoma cells, without the toxic side effects of systemic IL-2 treatment. The...
08:00 , Feb 8, 2010 |  BC Week In Review  |  Company News

Apeiron Biologics, GlaxoSmithKline deal

Apeiron granted GlaxoSmithKline exclusive, worldwide rights to develop and commercialize APN01. The recombinant human angiotensin-converting enzyme 2 (ACE2) is in Phase I testing to treat acute respiratory distress syndrome (ARDS). Apeiron will receive...
00:45 , Feb 4, 2010 |  BC Extra  |  Company News

GSK in-licenses Apeiron's APN01

Apeiron Biologics AG (Vienna, Austria) granted GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) exclusive, worldwide rights to APN01. The recombinant human angiotensin-converting enzyme 2 (ACE2) is in Phase I testing to treat acute respiratory distress syndrome. Apeiron will...